A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Trial details
- Registry ID
- NCT07465757
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as MLN8237; PB-8237
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)NCT07465757 | PBYI | Phase 2 | Recruiting | 2028-03-31Estimated |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerNCT06369285 | PBYI | Phase 2 | Recruiting | 2027-12-30Estimated |
| A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerNCT06095505 | PBYI | Phase 2 | Recruiting | 2027-10-30Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |